|
Oxford BioMedica PLC on Monday said it has completed the acquisition of the remaining 10% stake in its US subsidiary from Massachusetts, US-based biotechnology firm Q32 Bio Inc. The Oxford, England-based cell and gene therapy contract development and manufacturing company said the progression to full ownership of the subsidiary aligns with its global strategy and supports growth in the viral vector manufacturing market. Wholly-owned subsidiary OXB US Inc exercised its call option to buy the final 10% interest in OXB US LLC from Q32 in March. The stake was originally held by Homology Medicines Inc, which merged with Q32 last year. OXB US LLC was originally established in 2022 as an adeno-associated virus manufacturing and innovation business. Oxford Biomedica said the site has supported the onboarding of new programmes in the US as part of its global cell and gene therapy development and manufacturing network. ‘The progression to full ownership of our US business marks an important step for OXB. It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing - a critical enabler of the expanding cell and gene therapy market,’ said Chief Executive Officer Frank Mathias. ‘Our presence in the US, alongside our existing sites in the UK and France, gives clients access to deep expertise across AAV and lentiviral-based therapies. Through OXB’s network, we are able to support clients globally across all key vector types - from early-stage development through to commercialisation.’ Shares in Oxford BioMedica were down 3.0% at 311.50 pence in London at midday on Monday. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
